NA
GSK icon

NewEdge Advisors’s GSK GSK Stock Holding History

NewEdge Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.58M Buy
101,137
+6,583
+7% +$357K 0.02% 646
2025
Q4 		$4.64M Buy
94,554
+2,477
+3% +$116K 0.02% 688
2025
Q3 		$3.97M Sell
92,077
-5,335
-5% -$208K 0.02% 722
2025
Q2 		$3.74M Buy
97,412
+6,749
+7% +$258K 0.02% 683
2025
Q1 		$3.51M Buy
90,663
+7,148
+9% +$262K 0.02% 632
2024
Q4 		$2.82M Buy
83,515
+8,262
+11% +$297K 0.02% 683
2024
Q3 		$3.08M Buy
75,253
+5,205
+7% +$213K 0.02% 628
2024
Q2 		$2.7M Buy
70,048
+26,793
+62% +$1.13M 0.02% 642
2024
Q1 		$1.85M Buy
43,255
+1,911
+5% +$78.8K 0.02% 724
2023
Q4 		$1.56M Buy
41,344
+2,423
+6% +$87K 0.01% 755
2023
Q3 		$1.41M Buy
38,921
+13,302
+52% +$472K 0.02% 719
2023
Q2 		$913K Buy
25,619
+2,844
+12% +$102K 0.01% 909
2023
Q1 		$810K Sell
22,775
-526
-2% -$18.4K 0.01% 883
2022
Q4 		$324K Buy
+23,301
New +$776K 0.01% 968
2022
Q3 		– Sell
-17,786
Closed -$968K – 1581
2022
Q2 		$968K Sell
17,786
-2,332
-12% -$129K 0.02% 678
2022
Q1 		$1.09M Buy
20,118
+5,067
+34% +$275K 0.02% 613
2021
Q4 		$830K Buy
+15,051
New +$783K 0.01% 832
2020
Q3 		– Sell
-4,494
Closed -$229K – 945
2020
Q2 		$229K Sell
4,494
-7,445
-62% -$382K 0.01% 741
2020
Q1 		$565K Buy
11,939
+6,518
+120% +$348K 0.03% 426
2019
Q4 		$318K Buy
5,421
+52
+1% +$2.89K 0.01% 645
2019
Q3 		$286K Buy
5,369
+732
+16% +$37.7K 0.01% 648
2019
Q2 		$232K Buy
+4,637
New +$233K 0.01% 583
2018
Q4 		– Sell
-5,649
Closed -$284K – 662
2018
Q3 		$284K Buy
+5,649
New +$287K 0.02% 509
2017
Q3 		– Sell
-1,658
Closed -$87.5K – 668
2017
Q2 		$87.5K Buy
+1,658
New +$88.4K 0.02% 439

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

NewEdge Advisors's GSK Position: Q1 2026 in Review

NewEdge Advisors increased its GSK (GSK) stake by 7% in Q1 2026, buying an estimated $357K and bringing the position to 101,137 shares worth $5.58M. The position accounts for 0.02% of the portfolio, ranked #646.

NewEdge Advisors first reported a position in GSK in Q2 2017 and has held it in 24 quarters since. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • NewEdge Advisors held 101,137 shares of GSK worth $5.58M as of Q1 2026.
  • NewEdge Advisors bought 6,583 GSK shares in Q1 2026, an estimated $357K.
  • GSK made up 0.02% of NewEdge Advisors's portfolio in Q1 2026, its #646 holding.
  • NewEdge Advisors first reported a position in GSK in Q2 2017 and has held it in 24 quarters since.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.